# Coronavirus and Other Respiratory Viruses This page contains all datasets in the **Coronavirus And Other Respiratory Viruses** category of the CDC Open Data Catalog. **Total Datasets in Category**: 3 **Last Updated**: 5/24/2026 #### Examination of SARS-CoV-2 serological test results from multiple commercial and laboratory platforms with an in-house serum panel * **Description**: Severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) is a novel human coronavirus that was identified in 2019. SARS-CoV-2 infection results in an acute, severe respiratory disease called coronavirus disease 2019 (COVID-19). The emergence and rapid spread of SARS-CoV-2 has led to a global public health crisis, which continues to affect populations across the globe. Real time reverse transcription polymerase chain reaction (rRT-PCR) is the reference standard test for COVID-19 diagnosis. Serological tests are valuable tools for serosurveillance programs and establishing correlates of protection from disease. This study evaluated the performance of one in-house enzyme linked immunosorbent assay (ELISA) utilizing the pre-fusion stabilized ectodomain of SARS-CoV-2 spike (S), two commercially available chemiluminescence assays Ortho VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent Pack and Abbott SARS-CoV-2 IgG assay and one commercially available Surrogate Virus Neutralization Test (sVNT), GenScript USA Inc., cPass SARS-CoV-2 Neutralization Antibody Detection Kit for the detection of SARS-CoV-2 specific antibodies. Using a panel of rRT-PCR confirmed COVID-19 patients’ sera and a negative control group as a reference standard, all three immunoassays demonstrated high comparable positivity rates and low discordant rates. All three immunoassays were highly sensitive with estimated sensitivities ranging from 95.4%-96.6%. ROC curve analysis indicated that all three immunoassays had high diagnostic accuracies with area under the curve (AUC) values ranging from 0.9698-0.9807. High positive correlation was demonstrated among the conventional microneutralization test (MNT) titers and the sVNT inhibition percent values. Our study indicates that independent evaluations are necessary to optimize the overall utility and the interpretation of the results of serological tests. Overall, we demonstrate that all serological tests evaluated in this study are suitable for the detection of SARS-CoV-2 antibodies. * **Snowflake Schema**: dwv\_corona\_respiratory * **Databricks Schema**: cdc\_dwv\_corona\_respiratory * **Table Name**: sars\_cov2\_test\_results\_multiple\_platfor\_\_hhvg\_83jq * **Dataset ID**: hhvg-83jq * **Category**: Coronavirus and Other Respiratory Viruses * **Total Rows**: 612 * **Last Refresh**: 7/9/2025 * **Total Batches**: 3 * **Tags**: antibodies, covid-19, immunoassays, ncird-corvd, neutralization assay, sars-cov-2, serological tests * **Source Data**: #### Imputed Hospitalization Rate for RSV at the State Level * **Description**: Weekly imputed RSV hospital admission rates per 100,000 population from 47 states plus DC from 2018-2024 are described. Rates were estimated by combining values from RSV-Net with those from NSSP and NHSN to obtain combined time series of RSV hospital admissions counts. States with overlapping values in both sets underwent interpolation and extrapolation procedures for estimates throughout the time series. These states were then used to impute values for states that did not have surveillance data within RSV-Net. Calculated RSV hospital admission rates (either interpolated, extrapolated, or imputed) are reported. See the GitHub for code and further description. * **Snowflake Schema**: dwv\_corona\_respiratory * **Databricks Schema**: cdc\_dwv\_corona\_respiratory * **Table Name**: imputed\_hospitalization\_rate\_rsv\_state\_\_\_whhs\_7a5d * **Dataset ID**: whhs-7a5d * **Category**: Coronavirus and Other Respiratory Viruses * **Total Rows**: 14,258 * **Last Refresh**: 5/14/2026 * **Total Batches**: 1 * **Tags**: rsv, respiratory syncytial virus, respiratory illness, respiratory disease, rsvnet, surveillance, rate, nssp, hospitalizations, hospitalization rate, hospitalization * **Source Data**: #### NSSP Emergency Department Respiratory Daily * **Description**: NSSP Emergency Department Respiratory Daily. This dataset provides the percentage of emergency department patient visits for the specified pathogen of all ED patient visits for the specified geographic part of the country that were observed for the given day from data submitted to the National Syndromic Surveillance Program (NSSP).   For additional information, please see: Companion Guide: NSSP Emergency Department Data on Respiratory Illness While the data are stratified by day, updated data are available once per week each Wednesday. * **Snowflake Schema**: dwv\_corona\_respiratory * **Databricks Schema**: cdc\_dwv\_corona\_respiratory * **Table Name**: nssp\_emergency\_dept\_respiratory\_daily\_\_vjzj\_u7u8 * **Dataset ID**: vjzj-u7u8 * **Category**: Coronavirus and Other Respiratory Viruses * **Total Rows**: 18,991,584 * **Last Refresh**: 5/22/2026 * **Total Batches**: 74 * **Tags**: respiratory, nssp * **Source Data**: --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://docs.dataplex-consulting.com/data-catalog/cdc-open-data-product/cdc-coronavirus-and-other-respiratory-viruses.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.